本文關(guān)鍵詞： 高通量測(cè)序 乙型肝炎 Ion Torrent PGM Miseq 擴(kuò)增子測(cè)序 耐藥突變　出處：《中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院》2017年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：一、背景高通量測(cè)序(也稱(chēng)下一代測(cè)序技術(shù))技術(shù)具有強(qiáng)大的平行測(cè)序能力,被廣泛應(yīng)用于生命科學(xué)研究領(lǐng)域。近年來(lái)隨著成本的降低和應(yīng)用成熟度的增加,其在臨床基因檢測(cè)中備受青睞。高通量測(cè)序在用藥指導(dǎo)方面應(yīng)用廣泛,如腫瘤個(gè)體化治療基因檢測(cè),相對(duì)于傳統(tǒng)檢測(cè),更能全面覆蓋基因變異情況,為患者個(gè)體化用藥提供更多參考。乙型肝炎病毒(Hepatitis B virus:HBV)耐藥問(wèn)題嚴(yán)重,目前臨床用于治療慢性乙肝的藥物是核苷類(lèi)藥物,長(zhǎng)期治療都會(huì)引起不同程度的耐藥現(xiàn)象,密切監(jiān)測(cè)耐藥的產(chǎn)生,及時(shí)調(diào)整治療方案,已經(jīng)成為醫(yī)患關(guān)注的重點(diǎn)問(wèn)題。已知與耐藥相關(guān)的絕大部分突變均位于HBV聚合酶基因的逆轉(zhuǎn)錄酶區(qū)�，F(xiàn)有的檢測(cè)HBV突變方法有聚合酶鏈反應(yīng)(Polymerase chain reaction:PCR)直接測(cè)序法,由于靈敏度的限制,該方法只在群體中特定突變占20%以上時(shí)才能檢測(cè)到;PCR產(chǎn)物克隆測(cè)序法,可大致確定不同序列毒株之間的相對(duì)比例有助于發(fā)現(xiàn)混合株,但操作繁瑣且靈敏度有限。此外,實(shí)時(shí)定量PCR,限制性片段長(zhǎng)度多態(tài)性技術(shù),線性探針?lè)聪螂s交法在臨床使用中,雖然靈敏度各不相同,但都只能針對(duì)特定已知耐藥位點(diǎn),針對(duì)每一個(gè)位點(diǎn)分別設(shè)計(jì)探針/引物,效率低下。目前,下一代測(cè)序技術(shù)(Next generation sequencing:NGS)在HBV耐藥檢測(cè)中的應(yīng)用較少,尤其是具有實(shí)用價(jià)值的NGS檢測(cè)HBV耐藥突變方法未見(jiàn)報(bào)道。本文擬建立可用于臨床用藥指導(dǎo)的HBV耐藥基因位點(diǎn)高通量測(cè)序檢測(cè)方法,該方法能夠?qū)Π℉BV聚合酶基因內(nèi)的全部耐藥相關(guān)區(qū)段進(jìn)行分析,發(fā)現(xiàn)患者HBV耐藥位點(diǎn),為HBV感染患者的個(gè)體化治療提供依據(jù)。二、方法本文的第一部分是基于高通量測(cè)序的乙肝耐藥位點(diǎn)檢測(cè)方法的建立,首先針對(duì)耐藥位點(diǎn)所在區(qū)域設(shè)計(jì)特異引物,并對(duì)其進(jìn)行優(yōu)化;然后采用融合引物(Fusion method primer)策略設(shè)計(jì)適用于Thermo Life Ion Torrent PGM平臺(tái)及Illumina Miseq高通量測(cè)序平臺(tái)的引物,即在設(shè)計(jì)好的目標(biāo)特異引物的基礎(chǔ)上,添加適用于高通量測(cè)序的接頭和標(biāo)簽序列,以此引物擴(kuò)增乙型肝炎病毒脫氧核糖核酸(Hepatitis B virus Deoxyribonucleic acid,HBV DNA)獲得上機(jī)文庫(kù)。然后進(jìn)行測(cè)序操作獲得目標(biāo)區(qū)域的基因序列信息,并對(duì)其進(jìn)行分析。本文第二部分對(duì)基于高通量測(cè)序技術(shù)的乙肝耐藥突變位點(diǎn)檢測(cè)方法進(jìn)行驗(yàn)證和臨床樣本檢測(cè)。還利用以上建庫(kù)引物,對(duì)濃度梯度的HBV DNA標(biāo)準(zhǔn)物質(zhì)進(jìn)行了文庫(kù)構(gòu)建,以評(píng)價(jià)本方法的靈敏度;利用耐藥位點(diǎn)區(qū)域存在差異的兩種乙肝病毒基因組質(zhì)粒混合模擬樣對(duì)高通量測(cè)序方法的突變率檢測(cè)能力進(jìn)行評(píng)價(jià),選B型和C型HBV基因組質(zhì)粒按1:99,5:95,10:90三種比例混合建庫(kù),并在Ion Torrent PGM和Miseq上進(jìn)行上機(jī)測(cè)序,統(tǒng)計(jì)B型、C型兩種HBV DNA差異堿基的檢測(cè)效率;采用突變引物構(gòu)建HBV突變質(zhì)粒標(biāo)準(zhǔn)品,突變型和野生型HBV基因組質(zhì)粒按1:99,5:95,10:90三種比例混合建庫(kù),并在Ion Torrent PGM上進(jìn)行測(cè)序,統(tǒng)計(jì)突變堿基的檢測(cè)效率,對(duì)本研究設(shè)計(jì)的高通量測(cè)序方法的突變檢出能力進(jìn)行評(píng)價(jià)。進(jìn)一步,收集了15例慢性乙肝患者血液樣本,用Pure Link?Viral RNA/DNA Mini試劑盒提取HBV DNA。患者血清HBV DNA用建立的Ion Torrent PGM方法檢測(cè),樣本同時(shí)進(jìn)行Sanger法測(cè)序。三、結(jié)果1.對(duì)使用特異引物擴(kuò)增的PCR產(chǎn)物進(jìn)行毛細(xì)管電泳檢測(cè)分析產(chǎn)物長(zhǎng)度和測(cè)序驗(yàn)證序列,結(jié)果表明特異引物擴(kuò)增特異。PCR產(chǎn)物分為三個(gè)片段,大小分別是165bp、324bp和135bp,覆蓋的耐藥位點(diǎn)包括L80V/I,I169T,V173L,L180M,A181T/V,T184A,S202G/I,M204I/V/S,V214A,Q215S,N236T,M250V,G1896A。2.設(shè)計(jì)了Ion Torrent PGM的擴(kuò)增子引物和基于Miseq平臺(tái)的引物,并對(duì)引物擴(kuò)增產(chǎn)物進(jìn)行了毛細(xì)管電泳檢測(cè),結(jié)果表明產(chǎn)物長(zhǎng)度分別為244bp、467bp、320bp和296bp、559bp、218bp,一代測(cè)序證明其序列正確,表明測(cè)序引物擴(kuò)增正確;對(duì)構(gòu)建的質(zhì)粒標(biāo)準(zhǔn)品各步產(chǎn)物都采用毛細(xì)管電泳檢測(cè),構(gòu)建的質(zhì)粒采用毛細(xì)管電泳檢測(cè)和Sanger法一代測(cè)序鑒定,結(jié)果顯示HBV突變質(zhì)粒構(gòu)建成功。3.基于Ion Torrent?PGM平臺(tái)的融合引物建庫(kù)方法檢測(cè)靈敏度可達(dá)50IU/mL,建立了適用于Ion Torrent?PGM平臺(tái)和Miseq平臺(tái)的擴(kuò)增子文庫(kù)構(gòu)建方法,該方法可對(duì)HBV50 IU/mL的血清進(jìn)行建庫(kù)。對(duì)模擬樣中突變率在5%及其以上的位點(diǎn)可很好的檢出(信噪比10);對(duì)模擬樣中突變率在1%豐度的位點(diǎn)可檢出9/10,(信噪比10)。15例臨床樣品的檢出8個(gè)耐藥位點(diǎn),這些位點(diǎn)不能被臨床常用的Sanger法檢測(cè)到。四、結(jié)論初步建立了高通量測(cè)序檢測(cè)HBV耐藥突變的檢測(cè)方法,為臨床動(dòng)態(tài)監(jiān)測(cè)乙肝病毒耐藥位點(diǎn)突變、指導(dǎo)合理臨床用藥奠定了基礎(chǔ)。
[Abstract]:A background, high-throughput sequencing (also known as the next generation sequencing technology) technology has the strong ability of parallel sequencing, is widely used in the field of life science research. In recent years, with lower costs and application maturity increased, which favored in clinical genetic testing. High-throughput sequencing is widely used in medicine guidance, such as the individualized treatment of tumor gene detection, compared with the traditional detection, more comprehensive coverage of genetic variation, provide more reference for individualized medication. Patients with hepatitis B virus (Hepatitis B virus:HBV) resistance to the serious problem of current clinical medicine for treating chronic hepatitis B are nucleoside drugs, long-term treatment will cause varying degrees of resistance, close the resistance monitoring, timely adjust the treatment plan, has become a key problem of medical attention. Most of the known and resistance related mutations were located in HBV Reverse transcriptase region synthase gene HBV mutation detection. The existing methods of polymerase chain reaction (Polymerase chain reaction:PCR) direct sequencing method, because of the limit of the sensitivity of the method, only in the group specific mutations accounted for more than 20% can be detected; PCR cloning method, can roughly determine the relative ratio between different strains of sequence contribute to the discovery of mixed strains, but the operation is complicated and the sensitivity is limited. In addition, real-time quantitative PCR, restriction fragment length polymorphism technique, linear probes reverse hybridization in clinical use, although the sensitivity of each are not identical, but only to specific known mutation sites, for each site were designed probe / primer. The efficiency is low. At present, the next generation sequencing technology (Next generation sequencing:NGS) is seldom used in HBV resistance detection, especially the mutation detection of NGS HBV with practical value Methods have not been reported. This paper can be used to establish the HBV resistance gene loci high-throughput sequencing detection method to guide clinical medication, the method is able to include all resistant HBV polymerase gene related to the section analysis, found that patients with HBV mutations, and provide the basis for the individualized treatment of patients with HBV infection. In two, the first part of this method is the establishment of HBV resistance loci detection method based on high-throughput sequencing, aiming at the resistance locus specific primers and its optimization; then using fusion primers (Fusion method primer) primers for Thermo Life Ion design Torrent PGM platform and Illumina Miseq sequencing platform, which is based on specific goals primers on the joint and add tag sequences suitable for high-throughput sequencing, the amplified hepatitis B virus DNA (Hepatitis B virus Deoxyribonucleic RNA, acid, HBV DNA) to get on the library. Then the sequencing operation obtained gene sequence information of the target area, and carries on the analysis. The second part of the hepatitis B drug resistance high-throughput sequencing mutation detection method is verified and the detection of clinical samples. Based on the above database using primers HBV DNA standard material on the concentration gradient of library construction, according to the sensitivity of the method were evaluated by the mutation; there are two regions of hepatitis B virus genome plasmid of mixed model mutation on high-throughput sequencing method to evaluate the rate of detection ability, B type and C type HBV genome plasmid by 1:99,5:95,10:90 three mixed database, and computer in Ion Torrent and Miseq PGM sequencing, B statistics, detection efficiency of C type two HBV DNA different bases; the mutation lead Construction of HBV mutant plasmid, the mutant and wild type HBV plasmid genome by 1:99,5:95,10:90 three mixed library, and sequenced in Ion Torrent PGM, the detection efficiency statistics of mutation, mutation of high-throughput sequencing method designed in this paper, the detection ability evaluation. Further, a collection of 15 cases of chronic hepatitis B patients blood samples, using Pure Link? Viral RNA/DNA Mini HBV extraction kit of serum HBV in patients with Ion DNA. DNA Torrent PGM method to establish the sample detection, we carried out Sanger sequencing. Results 1. of three amplified using specific primers of PCR products were the length and sequencing analysis of capillary electrophoresis, results show that specific primer.PCR amplification product is divided into three segments, the size is 165bp, 324bp and 135bp, covering the resistance loci including L80V/I, I169T, V173L, L180M, A181T/V, T184A, S202G/I, M204I/V/S, V214A, Q215S, N236T, M250V, G1896A.2. Ion Torrent PGM designed amplification primers and primers based on the Miseq platform, and the amplified products were analyzed by capillary electrophoresis. The results showed that the product length were 244bp, 467bp, 320bp and 296bp, 559bp, 218bp, generation sequencing proved that the sequence of that is correct, correct amplification of plasmid sequencing primers; standard construction materials of the products by capillary electrophoresis, plasmid using capillary electrophoresis and Sanger generation sequencing, the results showed that HBV mutant plasmids were successfully constructed based on.3. Ion Torrent? PGM platform construction method of primer fusion detection sensitivity of 50IU/mL is established suitable for Ion Torrent amplification method for constructing PGM library? Sub platform and Miseq platform, the method of serum on HBV50 of IU/mL database. The simulation in the mutation rate in 5% and These sites can be detected very well (SNR 10); the mutation rate of 9/10 detection in 1% sites of abundance in synthetic samples, (SNR 10) detected 8 cases of.15 mutation of clinical samples, these sites cannot be detected in the commonly used Sanger method to clinical. Four, conclusion the mutation detection method of high-throughput sequencing to detect HBV resistant mutations, for the clinical dynamic monitoring of hepatitis B virus resistance loci, laid the foundation for guiding reasonable clinical medication.

【學(xué)位授予單位】：中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 劉俊濤;;高通量基因測(cè)序產(chǎn)前篩查與診斷技術(shù)規(guī)范解讀[J];中國(guó)產(chǎn)前診斷雜志(電子版);2016年01期

2 吳菲;呂鐵鋒;郭曉鳳;武靜;;阿德福韋酯耐藥株感染者乙型肝炎病毒基因型和多聚酶區(qū)基因變異分析[J];醫(yī)學(xué)研究雜志;2013年01期

3 陳成偉;陳從新;陳士俊;陳永平;成軍;程明亮;竇曉光;段鐘平;高志良;侯金林;賈繼東;江家驥;李杰;李蘭娟;李彤;魯鳳民;茅益民;繆曉輝;寧琴;�？∑�;任紅;斯崇文;孫永濤;譚德明;唐紅;唐小平;萬(wàn)謨彬;王德?lián)P;王貴強(qiáng);王豪;王慧芬;王宇明;魏來(lái);翁心華;謝青;楊益大;尤紅;張玲霞;張文宏;張欣欣;莊輝;;核苷和核苷酸類(lèi)藥物治療慢性乙型肝炎的耐藥及其管理[J];中國(guó)病毒病雜志;2013年01期

4 ;慢性乙型肝炎防治指南2010年更新版[J];中華實(shí)驗(yàn)和臨床感染病雜志(電子版);2011年01期

5 閆杰;溫少芳;王丹靜;吳淑玲;;乙型肝炎病毒耐藥專(zhuān)家共識(shí)[J];中華實(shí)驗(yàn)和臨床感染病雜志(電子版);2008年01期

，

本文編號(hào)：1509221